Citat:
Ursprungligen postat av
Onkel Kostia
Citat från länken:
COVID-19 infection rate was 39% lower among strict users [...] than in non-users (...), and non-significant 11% reduction compared to sporadic users (...) (...). Hospitalization rate was reduced by 100% in strict users, compared to non-users and to sporadic users, both before and after PSM (...). ... In propensity score matched groups, multivariate-adjusted mortality rate was 90% lower in strict users compared to non-users (...) and 79% lower than in sporadic users (...), while sporadic users had a 37% reduction in mortality rate compared to non-users (...). Risk of dying from COVID-19 was 86% lower among strict users than non-users (...) and marginally significant, 72% lower than sporadic users (...), while sporadic users had a 51% reduction compared to non-users (...).
Det där är ju jättebra siffror, i synnerhet med tanke på ivermektins gynnsamma biverkningsprofil. Man har mycket att vinna, och lite att förlora.
Tyvärr är det lite för sent att sätta in ivermektin nu. Nu håller epidemin på att närma sig slutet. Vet man huruvida ivermektin fungerar mot några andra virus? I så fall kan det bli ytterligare ett verktyg i verktygslådan i kampen mot virussjukdomar.
Several studies reported antiviral effects of ivermectin on RNA viruses such as Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki Forest, Sindbis, Avian influenza A, Porcine Reproductive and Respiratory Syndrome, Human immunodeficiency virus type 1, and severe acute respiratory syndrome coronavirus 2.
https://www.nature.com/articles/s41429-020-0336-z
